ClinicalTrials.gg
RecruitingNCT07365566PAIN-iRBDUpdated May 1, 2026

Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder

An interventional study of Thermo test pain and Pain questionnaires in REM Sleep Behavior Disorder (iRBD) and Narcolepsy Type 1, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in REM Sleep Behavior Disorder with a site in France — 6 open to participants now, 6 under way, none of them phase 3. REM Sleep Behavior Disorder · France.

Planned enrollment
8th of 10
24 · median 54
Started
2026
with 2 others
No phase
10 of 15
3 open now
Registered
14th of 15
by date
Lead sponsor
2 of 15
University Hospital, Toulouse

Among the 15 studies in REM Sleep Behavior Disorder with a site in France, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 14th registered.

REM Sleep Behavior Disorder

101 studies on the registry are indexed under REM Sleep Behavior Disorder; 45 are open to participants now.

Browse REM Sleep Behavior Disorder studies →

Open to participants now

6 of the 15 studies in REM Sleep Behavior Disorder with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 32 REM Sleep Behavior Disorder studies recruiting now, 18 (56%) set no upper age limit and 4 (13%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in REM Sleep Behavior Disorder with a site in France, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, with over 12 million patients expected globally by 2040. The disease is currently diagnosed at the appearance of motor symptoms, but by then, over 60% of striatal dopaminergic neurons have already been destroyed. Prodromal symptoms such as idiopathic REM Sleep Behavior Disorder (iRBD), anosmia, mood disorders and constipation appear earlier and are listed as criteria for a prodromal PD diagnosis. Identifying early signs is critical to initiate neuroprotective treatments as early as possible. While pain is prevalent and highly disabling in early PD, no data are currently available on pain perception in iRBD patients, whose condition is of the main risk factor for PD development.

03

Conditions studied

  • REM Sleep Behavior Disorder (iRBD)
  • Narcolepsy Type 1

Keywords

  • parkinson
  • REM sleep
  • pain
  • REM sleep behavior disorder
  • narcolepsy Type 1
  • sleep
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with iRBD confirmed by polysomnography;
  • No clinical diagnosis of Parkinson's disease or other diagnosis of neurodegenerative disease;
  • Ability to understand and complete study procedures and questionnaires;

Control group:

  • Diagnosed with narcolepsy type 1;
  • Coexisting REM sleep behavior disorder confirmed by polysomnography;
  • Ability to understand and complete study procedures and questionnaires;

Exclusion criteria

Exclusion Criteria:

  • Diagnosed Parkinson's Disease, dementia with Lewy bodies or multiple system atrophy;
  • Severe depression according to (DSM V);
  • Inability to complete study procedures or questionnaires.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Idiopathic REM sleep Behavior disorder (iRBD) Group

    Patients who have an idiopathic REM sleep Behavior Disorder

    Other: Thermo test pain · Other: Pain questionnaires · Other: No motors symptoms evaluations

  • Active comparator
    Idiopathic REM Sleep Bhavior Disorder (iRBD) + narcolepsy type 1

    patients who have an iRBD and who have type 1 narcolepsy

    Other: Thermo test pain · Other: Pain questionnaires · Other: No motors symptoms evaluations

Interventions

  • OtherThermo test pain

    Patients will undergo a pain test, also called a thermotest, which consists of determining pain thresholds using a thermometer applied to the hand.

  • OtherPain questionnaires

    Patients will complete various questionnaires about pain

  • OtherNo motors symptoms evaluations

    Patients will complete questionnaires

06

What researchers measure

Primary outcomes

  1. Comparison of the intensity of chronic pain between patients with iRBD and a control group of patients

    Measuring the Visual Analog Scale (VAS) between patients with iRBD without diagnosis of PD and a control group of patients diagnosed with narcolepsy type 1 who present RBD (Rapid eye movement sleep behavior disorder).

    Time frame: 2 hours after the inclusion

Secondary outcomes

  1. Describe semiological characteristics of pain in RBD patients

    Description of characteristics of pain

    Time frame: 2 hours after the inclusion

  2. Compare the presence of chronic pain

    Number of patients with chronic pain in both groups for at least 3 months.

    Time frame: 2 hours after the inclusion

  3. Assessing Pain Characteristics

    Score obtained on pain questionnaires

    Time frame: 2 hours after the inclusion

  4. Assessment of thermal pain threshold and tolerance

    Results of the quantitative sensory test (thermal thermotest) in both groups

    Time frame: 2 hours after the inclusion

  5. Assessment of correlations between the intensity of chronic pain

    Correlation between Visual Analogue Scale (VAS) measurements and questionnaire responses

    Time frame: 2 hours after the inclusion

07

Study locations

1 of 1 sites recruiting
  • Centre Expert Parkinson Hôpital Pierre Paul Riquet Place du Docteur Baylac
    Toulouse, 31059, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Aug 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 26, 2026
StartActual
Feb 24, 2026
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07365566
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Feb 24, 2026
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
May 1, 2026

Study contacts

Christine BREFEL COURBON
Contact
christine.brefel-courbon@univ-tlse3.Fr
05 61 77 60 39 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion